Weight, Diabetes, and Metabolic Health Hub

Navigator for the weight-management and metabolic clusters — whether any diet is superior for weight, whether type 2 diabetes can be put into remission, and where drugs enter as the realistic alternative. Nucleus of the weight side: Low-Carbohydrate vs Balanced-Carbohydrate Diets.

What BMI level minimizes mortality, and is the “obesity paradox” real?

• BMI and All-Cause Mortality — the bias-corrected BMI->mortality curve (Global BMI IPD-MA, 10.6M): nadir 22.5-25, monotone rise above 25 (HR 1.31 per 5 units, steepest in the young/men), and the «obesity paradox» shown to be a smoking/reverse-causation artifact — overweight walks from 0.96 (apparent protection) to 1.11 (harm) as biases are stripped -> The U-Shaped Association Artifact
• Ectopic Fat and Depot-Specific Risk — why BMI misleads at the individual level: risk tracks WHERE fat is stored (liver/pancreas overflow past a personal fat threshold) more than total mass. Normal- weight people can be above threshold; metabolically-healthy obesity is not durably benign (Kramer MHO MA); visceral fat is a marker for intra-organ fat, not the pathogenic depot. The ectopic-fat nucleus
• Waist-to-Hip Ratio and Cardiovascular Risk — which anthropometric marker best identifies MI risk: INTERHEART (case-control, 27,098, 52 countries) found WHR/waist far outrank BMI, whose whole MI association vanishes after adjusting for fat distribution (1.44 -> 1.12 -> 0.98); abdominal adiposity’s attributable share of MI is ~3x the BMI cut-point’s (24.3% vs 7.7%). Measure the waist, not the scale
• Weight Cycling and Cardiometabolic Risk — whether “yo-yo” dieting itself harms, and whether fear of it should deter attempting weight loss (confounding-caveated; the signal is in normal-weight body-image dieters, not obese patients — so not a reason to avoid trying)
• Chronic Kidney Disease and Modifiable Exposures — the CKD-prevention NUCLEUS: ranks the three modifiable levers (obesity, diet, physical activity) by effect x certainty. Obesity top and non-substitutable; diet next (He: healthy pattern OR 0.69, Western OR 1.86); PA weakest (Seidu: RR 0.91, GRADE very-low, prediction interval crosses 1). Configuration NOT convergence — three unlike exposures, not mutual corroboration; all observational; route-(a) absolute benefit largest in diabetic/hypertensive/high-BMI strata
• Obesity and Chronic Kidney Disease Risk — obesity predicts NEW-ONSET CKD (Garofalo MA, 39 cohorts / 630k): obesity -> low eGFR RR 1.28, albuminuria 1.51; overweight null; effect persists in metabolically-healthy obese (direct renal-hemodynamic path). Kidney joins CVD/cancer/liver as an organ the same weight lever protects; the RR is partly mediator-adjusted, so it under-states the total prevention benefit. Onset is in scope; progression is the prescriber boundary

Is any diet superior for weight loss?

• Low-Carbohydrate vs Balanced-Carbohydrate Diets — whether cutting carbohydrate beats a balanced diet for weight loss, answered as a pooled magnitude
• Named Diet Programs Compared — across branded programmes, whether any is clearly superior for weight and CV risk factors, and whether the benefit lasts
• Diets for Weight Loss - What NICE Recommends — which dietary approach to offer, to whom, and for how long, named as intervention/dose/duration rather than association
• Time-Restricted Eating — whether WHEN you eat, independent of what and how much, changes weight or cardiometabolic outcomes

Type 2 diabetes — prevention, control, and remission

• Lifestyle vs Metformin for Diabetes Prevention — in prediabetes, whether an intensive lifestyle program or metformin better prevents progression to T2D (the DPP head-to-head), and where the route-(b) effect-modification signal actually sits
• Diets for Weight Management in Type 2 Diabetes — for someone who already has T2D, whether any dietary approach is clearly superior for weight and glycaemic control
• Carbohydrate Restriction and Type 2 Diabetes Remission — whether restricting carbohydrate puts T2D into remission, and whether it lasts
• Total Diet Replacement and Type 2 Diabetes Remission — whether an energy-restricted total-diet- replacement programme achieves remission, and whether remission scales with weight loss
• Periodontitis and Systemic Health — does treating periodontitis lower HbA1c (causal, moderate certainty), and what the dementia arm can and cannot claim

Why maintenance is hard, and drug/monitoring routes

• Weight-Loss Maintenance and Metabolic Adaptation — why maintaining diet-induced loss is hard and whether the body physiologically defends the higher weight
• Comparing Obesity Drugs — the 19-drug network meta-analysis: how the class ranks on weight, hard outcomes, harms and QoL — and why the biggest weight loss is not the best-evidenced drug
• Semaglutide for Cardiovascular Risk in Obesity — whether treating obesity with a drug reduces CV events, and whether that evidence reaches primary prevention
• GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes — the class-level pooled hard-outcome page (Badve 2024, 11 CVOTs): what the whole GLP-1 class does to MACE, mortality and hard kidney events, and how that sizes the lifestyle weight-loss lever
• GLP-1 Non-Cardiometabolic Effects and Safety — the other half of the GLP-1 ledger: which non-cardiometabolic outcomes the class moves and how credible each signal is (gold umbrella)
• GLP-1 and Lean Mass — when a GLP-1 drug drives rapid loss, how much of what is lost is muscle, whether it exceeds ordinary weight loss, and what defends against it
• Semaglutide and Kidney Outcomes in Chronic Kidney Disease — for T2D + CKD, whether semaglutide reduces hard kidney and survival outcomes — a benefit beyond the CV/weight case (FLOW)
• Fatty Liver MASLD and Weight Loss — for fatty liver, which modifiable lever works, at what dose, and what outcome it actually changes
• Continuous Glucose Monitoring as a Health Intervention — whether wearing a CGM to guide eating improves outcomes, especially in people without diabetes